Privia Health Group (PRVA) Projected to Release Earnings on Thursday

Privia Health Group (NASDAQ:PRVA) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Privia Health Group to post earnings of $0.0683 per share and revenue of $597.7370 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Privia Health Group Stock Performance

Privia Health Group stock traded down $0.07 during trading hours on Tuesday, reaching $23.73. 140,408 shares of the company’s stock traded hands, compared to its average volume of 952,061. Privia Health Group has a fifty-two week low of $19.08 and a fifty-two week high of $28.82. The firm’s 50 day moving average is $24.53 and its 200-day moving average is $23.36. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of 148.42, a PEG ratio of 1.87 and a beta of 0.85.

Insider Activity at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 21,275 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $27.67, for a total value of $588,679.25. Following the completion of the sale, the chief financial officer directly owned 164,853 shares in the company, valued at $4,561,482.51. This represents a 11.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 53,722 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $27.24, for a total value of $1,463,387.28. Following the sale, the director directly owned 68,188 shares in the company, valued at approximately $1,857,441.12. This represents a 44.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 452,357 shares of company stock worth $11,436,655 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Privia Health Group

Several institutional investors and hedge funds have recently modified their holdings of PRVA. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Privia Health Group by 5.9% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock worth $385,000 after buying an additional 903 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in Privia Health Group by 16.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 14,395 shares of the company’s stock valued at $343,000 after acquiring an additional 1,997 shares in the last quarter. Headlands Technologies LLC acquired a new position in Privia Health Group during the 4th quarter worth approximately $316,000. Dynamic Technology Lab Private Ltd acquired a new position in Privia Health Group during the 4th quarter worth approximately $362,000. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Privia Health Group during the 3rd quarter worth approximately $305,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Weiss Ratings upgraded Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Barclays dropped their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, May 26th. Evercore set a $26.00 target price on Privia Health Group in a research note on Wednesday, April 8th. Canaccord Genuity Group reduced their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Finally, Zacks Research cut Privia Health Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.15.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.